|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0002520,
umls-concept:C0003209,
umls-concept:C0026769,
umls-concept:C0030705,
umls-concept:C0036043,
umls-concept:C0079189,
umls-concept:C0205263,
umls-concept:C0596383,
umls-concept:C0683278,
umls-concept:C0871261,
umls-concept:C0920321,
umls-concept:C1274040,
umls-concept:C1515999,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C2911692
|
|
pubmed:issue |
1-2
|
|
pubmed:dateCreated |
2010-8-20
|
|
pubmed:abstractText |
PI-2301 is an immunomodulator that could be an alternative therapy for MS. A placebo-controlled, multiple-ascending dose, double-blind study was performed in patients with secondary-progressive MS. Treatment was given subcutaneously once weekly for 8 weeks, followed by a 4-week open-label treatment period with active drug. The most common adverse event was transient injection site reactions. Non-significant trend for increases in serum levels of IL-3, IL-13, and CCL22 over time were suggestive of a beneficial T(H)2 immune response in subjects dosed with PI-2301 at 3 and 10 mg. MRI data indicated a non-significant trend for a reduction of lesion numbers in subjects treated with 1 and 3 mg PI-2301.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
1872-8421
|
|
pubmed:author |
pubmed-author:AugustyniakMM,
pubmed-author:BraudeauCC,
pubmed-author:CollinsKK,
pubmed-author:EdanGG,
pubmed-author:GenovaMM,
pubmed-author:HittingerTT,
pubmed-author:KovalchinJJ,
pubmed-author:KriegerJJ,
pubmed-author:KucaBB,
pubmed-author:MasciAA,
pubmed-author:MascioliEE,
pubmed-author:PatelUU,
pubmed-author:RimbertMM,
pubmed-author:ZanellaMM
|
|
pubmed:copyrightInfo |
Copyright 2010 Elsevier B.V. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
25
|
|
pubmed:volume |
225
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
153-63
|
|
pubmed:meshHeading |
pubmed-meshheading:20466440-Adult,
pubmed-meshheading:20466440-Anti-Inflammatory Agents,
pubmed-meshheading:20466440-Antibodies,
pubmed-meshheading:20466440-Cytokines,
pubmed-meshheading:20466440-Dose-Response Relationship, Drug,
pubmed-meshheading:20466440-Double-Blind Method,
pubmed-meshheading:20466440-Female,
pubmed-meshheading:20466440-Humans,
pubmed-meshheading:20466440-Magnetic Resonance Imaging,
pubmed-meshheading:20466440-Male,
pubmed-meshheading:20466440-Middle Aged,
pubmed-meshheading:20466440-Multiple Sclerosis, Chronic Progressive,
pubmed-meshheading:20466440-Peptides,
pubmed-meshheading:20466440-Severity of Illness Index,
pubmed-meshheading:20466440-Th2 Cells,
pubmed-meshheading:20466440-Treatment Outcome
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Results of a phase I study in patients suffering from secondary-progressive multiple sclerosis demonstrating the safety of the amino acid copolymer PI-2301 and a possible induction of an anti-inflammatory cytokine response.
|
|
pubmed:affiliation |
Peptimmune Inc., Cambridge, MA-02139, USA.
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Clinical Trial, Phase I
|
